AU3491897A - Vaccines comprising synthetic genes - Google Patents

Vaccines comprising synthetic genes

Info

Publication number
AU3491897A
AU3491897A AU34918/97A AU3491897A AU3491897A AU 3491897 A AU3491897 A AU 3491897A AU 34918/97 A AU34918/97 A AU 34918/97A AU 3491897 A AU3491897 A AU 3491897A AU 3491897 A AU3491897 A AU 3491897A
Authority
AU
Australia
Prior art keywords
vaccines
synthetic genes
genes
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU34918/97A
Other versions
AU728422B2 (en
Inventor
Mary-Ellen Davies
Daniel C. Freed
Margaret A. Liu
Helen C Perry
John W. Shiver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614942.2A external-priority patent/GB9614942D0/en
Priority claimed from GBGB9614943.0A external-priority patent/GB9614943D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU3491897A publication Critical patent/AU3491897A/en
Application granted granted Critical
Publication of AU728422B2 publication Critical patent/AU728422B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU34918/97A 1996-06-21 1997-06-17 Vaccines comprising synthetic genes Ceased AU728422B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2016696P 1996-06-21 1996-06-21
US2016596P 1996-06-21 1996-06-21
US60/020166 1996-06-21
US60/020165 1996-06-21
GBGB9614942.2A GB9614942D0 (en) 1996-07-16 1996-07-16 Synthetic HIV ENV genes
GBGB9614943.0A GB9614943D0 (en) 1996-07-16 1996-07-16 Vaccines comprising synthetic genes
GB9614942 1996-07-16
GB9614943 1996-07-16
PCT/US1997/010517 WO1997048370A2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes

Publications (2)

Publication Number Publication Date
AU3491897A true AU3491897A (en) 1998-01-07
AU728422B2 AU728422B2 (en) 2001-01-11

Family

ID=27451496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34918/97A Ceased AU728422B2 (en) 1996-06-21 1997-06-17 Vaccines comprising synthetic genes

Country Status (5)

Country Link
EP (1) EP0912607A2 (en)
JP (1) JP2000516445A (en)
AU (1) AU728422B2 (en)
CA (1) CA2258568A1 (en)
WO (1) WO1997048370A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1165798A2 (en) * 1999-03-29 2002-01-02 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
DE10053781B4 (en) * 2000-10-30 2008-07-03 Geneart Ag Nuclear export reporter system
EP2305699B1 (en) * 2001-06-05 2014-08-13 CureVac GmbH Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas for the vaccination against sleeping sickness, leishmaniosis and toxoplasmosis
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AU2003235707A1 (en) * 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
EP1578766B1 (en) * 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (en) 2011-03-31 2021-09-30 Modernatx, Inc. RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified nucleosides, nucleotides and nucleic acid compositions
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
LT2922554T (en) 2012-11-26 2022-06-27 Modernatx, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
CN112735525B (en) * 2021-01-18 2023-12-26 苏州科锐迈德生物医药科技有限公司 mRNA sequence optimization method and device based on divide-and-conquer method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
DE69536091D1 (en) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunization by vaccination of DNA transcription unit
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (en) * 1995-01-20 1996-08-06 Terumo Corp Dna vaccine
EP0904380B1 (en) * 1996-02-22 2005-11-09 Merck & Co., Inc. Synthetic hiv genes

Also Published As

Publication number Publication date
AU728422B2 (en) 2001-01-11
EP0912607A2 (en) 1999-05-06
CA2258568A1 (en) 1997-12-24
WO1997048370A2 (en) 1997-12-24
JP2000516445A (en) 2000-12-12
WO1997048370A3 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
AU3491897A (en) Vaccines comprising synthetic genes
AU4781297A (en) Vaccines
AU9623898A (en) Vaccines
AUPN864296A0 (en) Descender
AU2124697A (en) Synthetic hiv genes
AU3380897A (en) Synthetic hepatitis c genes
EP0958373A4 (en) Vaccines
AU4460497A (en) Mycosis vaccines
AUPN943096A0 (en) Descender
AU5763998A (en) Chlamydia vaccines
AU9655698A (en) Synthetic genes with immunomodulatory effects
AU3552797A (en) Vaccine preparations
AUPO060996A0 (en) Sexing gene
AU6075498A (en) Vaccines
GB9625968D0 (en) Vaccine
AU2541497A (en) Variant presenilin-2 genes
AU4785697A (en) Wand
GB9614943D0 (en) Vaccines comprising synthetic genes
ZA975417B (en) Vaccines comprising synthetic genes
AU3323197A (en) Improved support
GB9609252D0 (en) Vaccines
AU6293896A (en) Sarcocystis vaccine
AU2087297A (en) Descender
AUPO779197A0 (en) Novel vaccines
AUPO779297A0 (en) Novel vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)